| Chemomab Therapeutics is a biotechnology company focused on the discovery, development, and commercialization of targeted therapies to treat cancer. Co. is developing small-molecule pan-RAS inhibitors and inhibitors of phosphodiesterase (PDE10) and the ß-catenin pathway. Co.'s pan-RAS program has identified indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation, or pan-RAS inhibition. Co.'s PDE10/ß-catenin program has identified small molecules that inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling in preclinical models. We show 1 historical shares outstanding datapoints in our ANCN shares outstanding history coverage, used to compute ANCN market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ANCN market cap history over the course of time is important for investors
interested in comparing ANCN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ANCN versus a peer is one thing; comparing
ANCN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ANCN can fluctuate over the course of history.
With this page we aim to empower investors researching ANCN by allowing them to research the ANCN market cap history.